Boardroom overlooking a medical district at dusk

Andrew Hillman Advisory, Dallas

Dallas senior paralegal and healthcare compliance expert witness

Start with a Diagnostic
Andrew Jonathan Hillman of Dallas, Texas, speaking at an evening event in a blue plaid suit.

Press releases carried by

Modern hospital atrium with curved glass
Notebook, brass pen and tablet on a navy desk pad
Research microscope in teal backlight
Verified in the public record
SEC EDGAR CMS Provider Registry Crunchbase Wikidata Wikipedia ORCID OpenAlex Academia.edu
Margaret Hunt Hill Bridge and downtown Dallas skyline at sunset
Who he is
Advice from someone who ran these companies.
Andrew Jonathan Hillman is a Dallas senior paralegal and healthcare compliance expert witness, retained through counsel in federal matters nationwide. He is not an attorney. He is also the principal of Hillman Ventures, a private family office he founded in 1995. He has built and exited operating companies across surgical hospitals, clinical laboratories, pharmacy, intraoperative neuromonitoring, and medical devices. He now advises founders, investors, and boards on the decisions that decide whether a regulated healthcare company reaches the market.
The advice comes from someone who has been accountable for the outcome, not only for the memo.
What he does

Two services.

Each engagement starts with the constraint actually holding the business back. Then the work follows the order that money and regulators respond to.

01

Business growth consulting

Revenue, margin, and operating discipline for clinics, practices, diagnostics groups, and investor-backed healthcare services. Fix what is leaking before adding what is new.

Business growth consulting for healthcare and biotech
02

Regulatory strategy

Pathway mapping, milestone planning, and pressure-testing the clinical, operational, and compliance plan before it meets a regulator. Strategy support, not legal advice.

Regulatory strategy advisory for FDA-regulated ventures
The front door

The Diagnostic Advisory Engagement.

New clients start with a short, paid Diagnostic Advisory Engagement. It looks at growth performance and regulatory position together, because in an FDA-regulated business they are one system. What the regulator permits decides what you sell and when. A growth plan has to start there.

Step one

Kickoff session

We set the objective, the constraints, and what a useful answer looks like for you.

Step two

Document and data review

I go through what the business actually shows rather than what the deck says.

Step three

Working session

We test the findings against your reality and pressure the options together.

Step four

Final readout

The written strategy report lands, and we walk it end to end.

The engagement ends with a written strategy report and a live strategy session. The report gives you a clear picture of your growth performance and your regulatory position, and of how each one is constraining the other. The session turns that picture into concrete decisions and next steps. The report is something to take to your board, your investors, and your counsel.

After the diagnostic, clients either move into focused work on growth or regulatory strategy, or take the findings to their own team. The diagnostic stands on its own.

The Diagnostic Advisory Engagement
Discipline with capital is treated as a competitive advantage, not a constraint.
Operating principle
How I work

The decision sequence.

Recommendations follow a fixed order. Documented facts outrank narrative, and where the evidence is thin, the recommendation says so.

Step 01

Pathway first

The regulatory pathway is settled before anything else. It sets the requirements every later decision answers to.

Step 02

Test the evidence

Scientific and regulatory claims are weighed against primary sources, filings, and the published literature.

Step 03

Plan the capital

The capital plan is built to the pathway, with burn discipline and an operating cadence that matches the stage.

Step 04

Team and execution

The team and execution risk are tested against the plan. Assumptions are stated so a reader is able to check them.

Advisory work stays inside written scope and existing regulatory rules.

Operating history

The advice rests on a documented operating record.

1995
year Hillman Ventures was founded in Dallas

The operating history behind this advisory is documented in primary public sources, including SEC EDGAR filings and the CMS provider registry.

Prospective clients can review his background on Andrew Hillman, Dallas on LinkedIn before a first call.

Work history

Current roles and past companies.

Facts from the public record. Past means exited or sold. No ownership percentages are stated.

CURRENT
Principal, Hillman Ventures. A Dallas biotech family office, founded in 1995.
Senior paralegal and healthcare compliance and regulatory expert witness, retained through counsel. Not an attorney.
PAST ยท Hospitals
Victory Healthcare / Victory Medical Center facilities. Past ownership. Former Victory Hospitals were later acquired by Nobilis Health (2015).
Dynacq Healthcare / Vista Hospital / SSHA. Past hospital ownership.
PAST ยท Devices
Bone Solutions, Inc., Southlake, Texas. April 2016-November 2021.
PAST ยท Pharmacies (sold or exited)
The Apothecary Shop (Dallas, sold, now Executive Health, LLC), Progressive Pharma and Altus Pharmacy (Houston), Super Frisco Pharmacy, Centennial, and Frisco Pharmacy (Frisco).
PAST ยท Laboratories (exited)
Gulf Coast Toxicology, Central Texas Toxicology, East Texas Toxicology, National Toxicology, Digestive Laboratories, and Quality Lab Partners.
PAST ยท Anesthesia and staffing (exited)
Prime Anesthesia Staffing, First Assisting Specialists of Texas, and L2 Surgical.
PAST ยท Holding and management (exited)
RHZ, LLC, Optimized, Inc., Advanced Total Management, Energized, LLC, and Forge Realty Partners.

Source: andrewhillmanrecord.com.

Inquire

Start with a Diagnostic Advisory Engagement.

A brief qualifying exchange comes first, so we both know the diagnostic is the right use of your money. The fee is set out in the proposal, not on this page.

Andrew Hillman Advisory
Dallas, Texas, United States
Engagements are established only through a separate written agreement.
The Diagnostic Advisory Engagement
Connect on LinkedIn
Hillman Ventures
The Hillman Letter

Operator notes for advisory work.

Selected Letter essays on pathway, injunction risk, CMC, and regenerative enforcement. Strategy support, not legal advice.

The Hillman Letter · Latest · 2026-11-02
Zero Was True. The Claim Was Still False.
Six SNG dialysis centers pay about $2 million after reporting zero revenue to HRSA without disclosing a pre-arranged sale or closure. A true number in a misleading context still supports a False Claims Act theory.
Read on Substack
The Hillman Letter · 2026-10-26
1.25-1.6x Beats Treble: The Six-Month FCA Self-Disclosure Window
DOJ and HHS just put a price tag on coming forward: a 1.25 to 1.6x repayment for disclosing previously unknown civil False Claims Act issues. The clock runs to April 22, 2027.
Read on Substack
The Hillman Letter · 2026-10-19
The Spreadsheet Knew
Two September and October settlements show how a stalled internal review turns into a False Claims Act case. The 60-day overpayment clock is the reason.
Read on Substack
The Hillman Letter · 2026-09-21
The R3 Medical Warning Letter Is a Pattern, Not a Mood
What operators should extract from FDA warning-letter patterns in regenerative clinics.
Read on Substack
The Hillman Letter · 2026-08-16
The Permission Gap
Twelve states rewrote regenerative medicine law in eighteen months. Federal law did not move. Here is what that costs you.
Read on Substack
The Hillman Letter · 2026-08-11
Sponsor kills ExoFlo perianal fistula trial after enrolling five patients
The sponsor terminated its ExoFlo trial in perianal fistula (NCT05836883) on August 11.
Read on Substack
The Hillman Letter · 2026-07-27
The CMC chasm. Why most biotech IND submissions fail at chemistry, not biology.
The biology is usually right. The chemistry, manufacturing, and controls package is where most IND submissions fail.
Read on Substack

Archive: thehillmanletter.substack.com

Frequently asked questions

Advisory, answered.

What does Andrew Hillman do?
Andrew Hillman is a Dallas senior paralegal and healthcare compliance expert witness. Through this practice he also advises healthcare, biotech, and investor-backed companies on growth and regulatory strategy. It is strategy support, not legal advice.
How do new clients start with Andrew Hillman?
New clients start with a short, paid Diagnostic Advisory Engagement. A brief qualifying exchange comes first to confirm fit. The diagnostic assesses growth performance and regulatory position together, and ends with a written strategy report and a live strategy session.
Does Andrew Hillman offer a free consultation?
No. There is a brief qualifying exchange to confirm fit, and then new clients begin with a paid Diagnostic Advisory Engagement. The diagnostic stands on its own and is not a sales call with a fee attached. The fee is set out in the proposal.
What is included in business growth consulting?
Work on revenue, margin, operating discipline, and decision quality, with the scope set in writing before the work begins.
What does regulatory strategy advisory cover?
Pathway mapping, milestone planning, pressure-testing clinical, operational, and compliance plans, and preparing leadership for FDA and CMS engagement. It is strategy support, not legal advice, and no regulatory outcome is promised.
Where is Andrew Hillman based?
Andrew Hillman is based in Dallas, Texas.
Does Andrew Hillman have a podcast?
Yes, Andrew J. Hillman hosts The Hillman Letter Podcast, which covers healthcare fraud and abuse law, The Hillman Letter, his published work and his giving record in plain English. Episodes use synthetic AI narration and are educational only, not legal advice.
Connect

Publications

Andrew Jonathan Hillman's works are listed on ORCID 0009-0001-5396-321X and deposited on Zenodo with permanent DOIs.

Exosome and mesenchymal stem cell derived extracellular vesicle products are not approved by the FDA for any indication. The work referenced here describes published scientific literature. It does not describe an available treatment.

Expert witness page: Dallas Healthcare Compliance Expert Witness.

Profiles and identifiers

Andrew Jonathan Hillman

Dallas senior paralegal and healthcare compliance expert witness. Not an attorney.

Expert witness page · Publications · Book a meeting

Beyond advisory: andrew-hillman.com and hillmanv.com.

Profiles

Press

Sites